



XTACY Therapeutics Corporate Update

New Debt Settlement

Vancouver: May 13, 2024 – Xtacy Therapeutics Corp. (Formerly Global Wellness Strategies Inc.) (CSE: XTCY) (Frankfurt: TT5) (OTC: XTCYF) (“the Company) announces future plans of their investees and announces new debt settlements.

Over ten years ago it was hinted that perhaps nutraceuticals could be considered for more than nutrition and also to be used as medicine. Nutraceuticals were then defined as substances that could have protection against even chronic diseases. Today, not only are there consumer products formulated with functional mushrooms, but both cannabis, cannabidiol, cannabinol, cannabigerol and soon psychedelics as famous as MDMA aka Molly, LSD, ketamine and psilocybin are becoming mainstream to benefit one’s health and wellness and even improve our lifestyles. Immunotherapy was almost considered sorcery, and it used to be all about a chicken soup, a hot steam and not about boosting our immune systems with developed molecules to fight off even the most malignant cancers and diseases. 2024 is quickly becoming the breakthrough year of Xtacy Therapeutics. Our investees have taken the lead and our investors who have supported us are introducing us to capital streaming sources from Australia, to Europe to Canada.

- We are hopeful that we are closer to our MDMA trials with the help of our Australian partners and their introduction to a strong fund in Australia. iGENU CRO Pty Ltd is quickly becoming the CRO house of psychedelic leaders and trials in the global industry. We are fortunate to have a strong relationship with iGENU's founder and a medical advisor of Xtacy, Dr. Sud Agarwal. He is also the Co-Founder of Cannvalate in Australia.
- KaleidoMyco is soon to be launching a new education site on the benefits of medicinal mushrooms and cannabinol (CBN) and cannabigerol (CBG), in conjunction with their consumer products. Global leader Leah Kincaid is still the source for all our formulae and we are working on filing patents shortly on her newest formulated molecules in the USA.

The Company has agreed with certain of its creditors to issue an aggregate of 3,272,727 common shares (the "Settlement Shares") to such creditors in exchange for outstanding accounts payable (the "Shares for Debt Transaction") in the aggregate amount of CA\$180,000 (the "Debt") owing to certain creditors (the "Creditors"). The Settlement Shares are being issued at a price of \$0.05, in accordance with the policies of the Canadian Securities Exchange (the "CSE"). The Company is completing the Shares for Debt Transaction to improve its financial position by reducing its existing liabilities. The securities issued in connection with the Debt Settlement will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation. Pursuant to the policies of the Canadian Securities Exchange, the Debt Settlement will close five business days from the date of this press release. The Shares for Debt Transaction remains subject to CSE acceptance

About Xtacy Therapeutics Corp. :

Xtacy is a prospect generator that provides high growth companies with financial, operational, and

management assistance in the fast growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies and their clinical studies and trials.

For further information visit website:

www.xtacytherapeutics.com

Or Contact Meris Kott CEO email to info@xtacytherapeutics.com (604) 484-0355

Further information about the Company is available on www.SEDARplus.com under the Company's profile.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.